#426: Recursion And Exscientia Are Merging To Form An AI-Enabled Drug Discovery Powerhouse, & More

Last week, Recursion and Exscientia agreed to a merger that we believe is a visionary step forward in the AI-driven transformation of drug discovery. Uniting Recursion’s pioneering biological exploration capabilities with Exscientia’s AI precision chemistry, the partnership could catapult the biopharma industry into a new way of discovering and developing medicines.